AOD-9604, short for Anti-Obesity Drug-9604, is a synthetic analog of the human growth hormones lipolytic (fat-burning) region
Yes, many patients experience significant weight loss with compounded sublingual semaglutide
NEDA cautions that for people with active eating disorders or a history of disordered eating, these drugs can be harmful when not used for their intended purpose, when inadequately monitored or monitored by clinicians without eating disorder expertise, or when used for weight loss motivated by weight stigma. That doesnt mean GLP-1s are automatically off the table, but it does mean that this decision warrants extra care, specialist input, and close monitoring throughout
The Beyond-Use Date (BUD) for most compounded semaglutide formulations is up to 60 days when stored under proper refrigeration, though individual pharmacies may assign shorter dating based on their specific testing
Gallstone formation risk increases during any significant weight loss, and GLP-1 therapy is no exception